Radotinib
- Generic Name
- Radotinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H21F3N8O
- CAS Number
- 926037-48-1
- Unique Ingredient Identifier
- I284LJY110
- Background
Radotinib is under investigation for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
- Indication
Radotinib is indicated for the treatment of different types of cancer, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance of other Bcr-Abl tyrosine-kinase inhibitors, such as patients resistant or intolerant to imatinib.
- Associated Conditions
- -
- Associated Therapies
- -
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath